A phase II trial of the FGFR inhibitor pemigatinib in patients with metastatic esophageal-gastric junction/gastric cancer trastuzumab resistant: the FiGhTeR trial

Therapeutic Advances in Medical Oncology
Valeria MerzDavide Melisi

Abstract

Prognosis of patients affected by metastatic esophageal-gastric junction (EGJ) or gastric cancer (GC) remains dismal. Trastuzumab, an anti-HER2 monoclonal antibody, is the only targeted agent approved for the first-line treatment of patients with HER2-overexpressing advanced EGJ or GC in combination with chemotherapy. However, patients invariably become resistant during this treatment. We recently identified the overexpression of fibroblast growth factor (FGF) receptor 3 (FGFR3) as a molecular mechanism responsible for trastuzumab resistance in GC models, providing the rationale for the inhibition of this receptor as a potential second-line strategy in this disease. Pemigatinib is a selective, potent, oral inhibitor of FGFR1, 2, and 3. The FiGhTeR trial is a phase II, single-arm, open-label study to assess safety and activity of the FGFR inhibitor pemigatinib as second-line treatment strategy in metastatic EGJ/GC patients progressing under trastuzumab-containing therapies. The primary endpoint is the 12-week progression-free survival rate. Plasma and tumor tissue samples will be collected for translational research analyses at baseline, during treatment, and at progression on pemigatinib. Co-alterations in genes coding for diff...Continue Reading

References

Jan 9, 2013·Annals of Internal Medicine·An-Wen ChanDavid Moher
Jul 17, 2013·Current Opinion in Pharmacology·Davide MelisiGiampaolo Tortora
Jun 17, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Mehdi TouatJean-Charles Soria
Oct 10, 2015·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Emanuele ValtortaMarcello Gambacorta
Jun 9, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Geny PiroDavide Melisi
Sep 1, 2016·International Journal of Cancer. Journal International Du Cancer·F PietrantonioM Di Bartolomeo
Oct 26, 2016·BMJ : British Medical Journal·Sandra M EldridgeUNKNOWN PAFS consensus group
Dec 29, 2016·Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association·Valentina FanottoGiuseppe Aprile
Apr 7, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ariella B HankerCarlos L Arteaga
Nov 11, 2017·Cancer Discovery·Yelena Y JanjigianNikolaus Schultz
Jan 4, 2020·Journal of Gastric Cancer·Alessandro CavaliereDavide Melisi
Mar 14, 2020·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel V T CatenacciZev A Wainberg

❮ Previous
Next ❯

Citations

Mar 2, 2021·Frontiers in Cell and Developmental Biology·Chengyi MaoYong Yuan
May 21, 2021·Journal of Pharmaceutical and Biomedical Analysis·Qinghua WengYu Chen
Aug 17, 2021·Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association·Akira Ooki, Kensei Yamaguchi
Aug 21, 2021·Bioorganic & Medicinal Chemistry·Thais Cristina Mendonça Nogueira, Marcus Vinicius Nora de Souza

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsies
biopsy
contraception
immunoprecipitation

Clinical Trials Mentioned

NCT02393248
NCT02872714
NCT03656536

Software Mentioned

FiGhTeR
REDCap

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

© 2021 Meta ULC. All rights reserved